Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
This can delay reaching the therapeutic dose and, consequently, the full clinical benefits
Circulating MOTS-c declines with age and tracks with insulin resistance, making it both a potential longevity biomarker and a therapeutic target
Also in July, the European Commission (EC) approved Trodelvy (sacituzumab govitecan) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting
To see how a filler-free, 26-strain synbiotic was built around these principles, explore our complete guide to MicroBiome Restore
The K7M2 cells were maintained in DMEM, also supplemented with 10% FBS and 1% P/S
US$ 21.47
US$ 23.46
US$ 20.02
US$ 27.09
US$ 26.32
US$ 28.59
